

IVIIG reimbursement in Czech Republic



Anna Sediva
Institute of Immunology
Prague, Czech Republic

Czech Republic




history of
immunology in
Czechoslovakia

Czech Immunology



Gregor Mendel
genetics




"Czech School of Immunology"
founded by Milan Hašek,
co-discoverer of the
immunological tolerance
phenomenon.

Czech clinical immunology immunodeficiencies



Prof. Good in
Czechoslovakia
1969




First book on
immune
deficiencies
1979



„bubble boy“
1980

XLA - Bruton agammaglobulinemia case report history of Czech patients



Dystonia Deafness Protein
DDP
Mohr-Tranebjaerg
syndrome,
mitochondrial
disease



two brothers with atypical
form of XLA

typical clinical
symptomatology of XLA
associated with
deafness and mental
retardation


exon 19 deletion of BTK
deletion of DDP
X 22q
,contiguous deletion
syndrome'

Diagnosis and therapy in time




1975-1980

diagnosis made on clinical picture and laboratory investigation of humoral immunity



1980-1995

substitution - plasma or IVIG
czecho-slovak production



1983-1984

first flow cytometer in Czechoslovakia
missing B lymphocytes

Allergic reactions, complications. Discontinued in 90's.

Diagnosis and therapy in time



1993

XLA gene discovery

1995

deletion of exon 19



2000

Continuous deletion syndrome

2002-2004

mitochondrial disease

ESID



2004

Patients in USA and Lithuania

molecular diagnostics in
Czech Republic

Time, Czechoslovakia and IVIG




1945



1957


IMUNA –
plasma fractionation
Šarišské Michalany



1968

Time, Czechoslovakia and IVIG

communism



capitalism

socialistic
state directed
health care system

1989
velvet revolution

gradual
development of
health insurance

Czech IVIG partly covered

European IVIG partly covered

ESID and European cooperation

Diagnostic
guidelines

www.esid.org



Therapeutic
guidelines


IVIG

sc immunoglobulins

Primary immunodeficiencies

- humoral
- cellular
- phagocytic
- complement
- other




Europe



Czech Republic



Inst. of Immunology



IVIg current situation, Czech Republic immunodeficiencies




centers for ID
excellent clinical
effect

reimbursement policies
frequent changes
uncertainty

IVIg current situation, Europe immunodeficiencies

		hospital care	out-patient care
Czech Republic		covered	reimbursement based on fixed sum, problems with new patients
France		covered	covered
Germany		covered if > 24g/dose	covered
Greece		covered at the moment	γ -globulin is not allowed for outpatient care, yet
Hungary		covered	covered
Netherlands		covered	insurance company has to approve beforehand, but mostly it is covered
Poland		covered	covered
Spain		covered	covered
Sweden		covered	partly covered home care
United Kingdom		covered	covered

IVIg current situation, Czech Republic autoimmunity



1 g 4×10^{18} molecules IgG

Kawasaki disease
ITP

others

reimbursed on an
individual basis

IVIg current situation, Czech Republic problems




money

Low immunoglobulins, no
infection?

Near normal immunoglobulins
with infections?

Autoimmunity?

IVIG perspectives



substitution based on
therapeutic guidelines
production of specific molecular
targeted IVIG
IVIG in autoimmune diseases

IVIG in cancer
molecular technologies in IVIG
production
IVIG production in plants
mucosal immunoglobulins

